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Implication for health policy/practice/research/medical education:
In a study on 36 stable hemodialysis patients, we found, the inverse correction of leptin with C-reactive protein level. Our data supports, the 
positive effect of leptin on nutrition and support the theory of protective effects (reverse epidemiology) of leptin in hemodialysis patients.
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Introduction
Recent investigations have shown that leptin is cleared 
principally by the kidney. Serum leptin levels are increased 
in patients with chronic kidney failure and those undergoing 
hemodialysis (1,2) and it has been thought that high leptin 
value may contribute to uremic anorexia and malnutrition 
(4,5). In the general population leptin is considered an “appetite 
inhibitor”, however in contrast to preliminary findings, its 
role in chronic renal disease and hemodialysis patients is not 
completely found. While serum leptin is generally elevated in 
chronic kidney failure and hemodialysis patients, however, 
some other studies have not been shown to be a cause of 
uremia-related anorexia (6,7). More recent investigations 
in hemodialysis patients suggest a paradoxically inverse 
correction between higher serum leptin and improved markers 
of nutritional condition (6,7), a finding that is indicative of 
reverse epidemiology in this population (8). In fact, leptin, 
similar to serum albumin, has been reported to be a negative 
acute phase reactant in end-stage kidney failure (7). C-reactive 
protein (CRP) is an acute phase protein whose synthesis in 
the liver. CRP is regulated by different cytokines, especially 
interleukin 6 (IL-6). Plasma level of CRP in the absence of 
active disease are low, but can rise up to 1000-fold in patients 
with an inflammatory reaction. In addition to being a marker 
of inflammation, CRP itself may have pro-inflammatory 
properties while it can activate the complement system (8,9). 
Therefore elevated plasma concentrations of CRP, a sensitive 
marker of underlying systemic inflammation (10-12). Serum 
CRP value have also been shown to be significantly elevated 
in patients on hemodialysis (13,14) and suggests chronic 
inflammation. Serum CRP, is a sensitive and independent 
marker of malnutrition (15). According to the present data, 
investigations concerning the association of CRP with serum 
leptin needs further examination.
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Introduction: Recent investigations have shown that leptin is cleared principally by the kidney.
Objectives: To examine whether and how in patients on hemodialysis the level of C-reactive protein level 
correlate with serum leptin. 
Patients and Methods: The total patients were 36. The mean patients’ age were 46 (16) years. The median 
length of the time patients were on hemodialysis were 19 months. 
Results: The mean serum C-reactive protein was 8.7 (6.6) mg/l (median: 8 mg/l). The mean serum leptin 
was 9.4 (14) ng/ml (median: 5.75 ng/ml). In this study we found a significant inverse correlation of serum 
leptin   with serum C-reactive protein (r= -0.57, p= 0.041) was seen. 
Conclusion: Our data supports, the positive effect of leptin on nutrition and support the theory of 
protective effects (reverse epidemiology) of leptin in hemodialysis patients.
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Objectives
The aim this study was to elucidate whether and how in 
patients on hemodialysis the serum value of CRP as the marker 
of inflammation correlate with serum leptin.
Patients and Methods 
Patients 
This cross-sectional study was conducted on patients with 
end-stage kidney disease, who were undergoing regular 
hemodialysis. The study was conducted in hemodialysis 
section of Shahrekord University of Medical Sciences. 
Laboratory assessments
Blood samples were obtained after an overnight fast. For 
patients, Levels of serum CRP, leptin (normal range of values 
for males is 3.84 (1.79) and for females is 7.36 (3.73) ng/ml were 
measured by enzyme-linked immunosorbent assay (ELISA). 
Duration and doses of hemodialysis treatment were calculated 
from the patients’ records. The duration of each hemodialysis 
session was 4 hours. For the efficacy of hemodialysis the urea 
reduction rate (URR) was calculated from pre- and post-
blood urea nitrogen (BUN) data (16). Body mass index (BMI) 
calculated using the standard formula (postdialyzed weight in 
kilograms/height in square meters; kg/m2) (17).
Ethical approval
All patients signed the consent form for participation in this 
study. Research study was approved by the ethics committee of 
Shahrekord University of Medical Sciences, Iran.
Statistical analysis
Results are expressed as the mean (SD) and median values. 
Statistical correlations were assessed using partial correlation 
test. For leptin correlation,  the logarithm of serum leptin 
values was used. All statistical analyses were performed using 
SPSS (version 12.00). Statistical significance was determined at 
a p-value < 0.05.
Results
Study patients were 36. Table 1 shows patients’ data. The 
mean patients’ age were 46 (16) years. The mean length of the 
time patients had received hemodialysis was 32 (36) months. 
The mean serum CRP was 8.7 (6.6) mg/l. The mean serum 
leptin was 9.4 (14) ng/ml (median: 5.75 ng/ml). In this study 
a significant inverse correlation of serum leptin   with  serum 
CRP  (r= -0.57, p= 0.041) was seen. 
Discussion 
In this study we detected a significant inverse correlation of 
serum leptin   with CRP value. The increased levels of leptin 
in hemodialysis patients are mainly due to retention of the 
hormone. Recent studies in maintenance dialysis patients 
suggest a paradoxically inverse association between higher 
Table 1. Data of patients.
Total patients= 36 Minimum Maximum Mean (SD) Median
Age   (years) 16 80 46(16) 43
DH*  ( months) 2 156 32(36) 19
CRP   mg/l 3 40 8.7(6.6) 8
Mg   mg/dl 1.6 3.5 2.5±0.4 2.4
serum leptin and improved markers nutritional status 
(6,7), a finding  that  is in accord with the theory of reverse 
epidemiology (8,18-21). Indeed, leptin, similar to serum 
albumin, has been reported to be a negative acute phase 
reactant in hemodialysis patients (7). While, in the general 
population, leptin is considered an “appetite inhibitors”, its role 
in hemodialysis patients is somewhat different. Serum leptin 
is generally elevated in hemodialysis, but this has not been 
shown to be related to anorexia. In contrast leptin has been 
shown to act synergistically with erythropoietin to stimulate 
the end-stage colony-forming-unit erythroid in humans (22).
Conclusion
Our data indirectly supports the some previous investigations 
regarding the hypothesis that in patients on hemodialysis, 
leptin is a negative acute phase reactant and leptin might 
have a positive effects on nutrition and support the theory of 
protective effects of leptin in hemodialysis patients.
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